ABCG2 Protein Levels and Association to Response to First-Line Irinotecan-Based Therapy for Patients with Metastatic Colorectal Cancer.
ATP Binding Cassette Transporter, Subfamily G, Member 2
/ analysis
Aged
Biomarkers, Tumor
/ analysis
Colon
/ drug effects
Colorectal Neoplasms
/ drug therapy
Female
Humans
Irinotecan
/ therapeutic use
Male
Middle Aged
Neoplasm Metastasis
/ drug therapy
Neoplasm Proteins
/ analysis
Rectum
/ drug effects
Retrospective Studies
Topoisomerase I Inhibitors
/ therapeutic use
ABCG2 protein
BCRP
biomarker
colorectal cancer
irinotecan
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
16 Jul 2020
16 Jul 2020
Historique:
received:
07
06
2020
revised:
12
07
2020
accepted:
13
07
2020
entrez:
26
7
2020
pubmed:
28
7
2020
medline:
23
2
2021
Statut:
epublish
Résumé
In this study we investigated the use of cancer cell protein expression of ABCG2 to predict efficacy of systemic first-line irinotecan containing therapy in patients with metastatic colorectal cancer (mCRC). From a Danish national cohort, we identified 119 mCRC patients treated with irinotecan containing therapy in first-line setting. Among these, 108 were eligible for analyses. Immunohistochemistry (IHC) analyses were performed on the primary tumor tissue in order to classify samples as high or low presence of ABCG2 protein. Data were then associated with patient outcome (objective response (OR), progression free survival (PFS) and overall survival (OS)). ABCG2 protein expression in the basolateral membrane was high (score 3+) in 33% of the patients. Exploratory analyses revealed a significant interaction between ABCG2 score, adjuvant treatment and OR (
Identifiants
pubmed: 32708825
pii: ijms21145027
doi: 10.3390/ijms21145027
pmc: PMC7404184
pii:
doi:
Substances chimiques
ABCG2 protein, human
0
ATP Binding Cassette Transporter, Subfamily G, Member 2
0
Biomarkers, Tumor
0
Neoplasm Proteins
0
Topoisomerase I Inhibitors
0
Irinotecan
7673326042
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : IMK Almene
ID : 102-0489/13-3000
Organisme : Savværksejer Ivita and Jeppe Juhl Foundation,
ID : 102-5212/18-3000
Organisme : Danish Cancer Society Research Center
ID : DK001
Organisme : Danish Cancer Society Research Center
ID : DCSR010
Organisme : Kathrine and Vigo Skovgaard Foundation
ID : KVSF010
Organisme : the Danish Strategic Research Counsel
ID : DSRC010
Organisme : I.M. Daehnfeldt Foundation.
ID : IMDF010
Références
Methods Mol Biol. 2010;596:251-90
pubmed: 19949928
Int J Biochem Mol Biol. 2012;3(1):1-27
pubmed: 22509477
Int J Cancer. 2004 May 10;109(6):848-54
pubmed: 15027118
J Clin Oncol. 2009 Jul 1;27(19):3117-25
pubmed: 19451425
Mol Pharmacol. 2013 Nov;84(5):655-69
pubmed: 24021215
Nat Rev Cancer. 2002 Jan;2(1):48-58
pubmed: 11902585
J Natl Cancer Inst. 2009 Nov 4;101(21):1446-52
pubmed: 19815849
Br J Pharmacol. 2011 Dec;164(7):1767-79
pubmed: 21175590
Basic Clin Pharmacol Toxicol. 2020 Jul 6;:
pubmed: 32628359
Sci Rep. 2016 Jun 03;6:26997
pubmed: 27257141
Mol Oncol. 2015 Jun;9(6):1169-85
pubmed: 25759163
Cells. 2019 Dec 19;9(1):
pubmed: 31861708
JAMA. 2017 Jun 20;317(23):2392-2401
pubmed: 28632865
Cancer Biomark. 2013;13(2):81-8
pubmed: 23838136
Asian Pac J Cancer Prev. 2010;11(4):845-8
pubmed: 21133588
Int J Cancer. 2015 Mar 1;136(5):E359-86
pubmed: 25220842
Lancet. 2000 Mar 25;355(9209):1041-7
pubmed: 10744089
Clin Cancer Res. 2016 Apr 1;22(7):1621-31
pubmed: 26542057
Clin Cancer Res. 2001 Apr;7(4):935-41
pubmed: 11309344
J Clin Oncol. 2004 Jan 15;22(2):229-37
pubmed: 14657227
Cancers (Basel). 2020 Apr 15;12(4):
pubmed: 32326511
World J Gastroenterol. 2013 Oct 21;19(39):6630-6
pubmed: 24151392
Ann Oncol. 2014 Sep;25 Suppl 3:iii1-9
pubmed: 25190710
Oncol Lett. 2016 Oct;12(4):2752-2760
pubmed: 27698852
BMC Med. 2012 May 29;10:51
pubmed: 22642691
Adv Drug Deliv Rev. 2009 Jan 31;61(1):3-13
pubmed: 19135109
Korean J Physiol Pharmacol. 2012 Feb;16(1):11-6
pubmed: 22416214
J Clin Oncol. 2011 Aug 20;29(24):3328-30
pubmed: 21788567
J Natl Cancer Inst. 2000 Feb 2;92(3):205-16
pubmed: 10655437
Mod Pathol. 2012 May;25(5):637-50
pubmed: 22222640
Nat Rev Cancer. 2018 Jul;18(7):452-464
pubmed: 29643473
Int J Mol Sci. 2017 Sep 07;18(9):
pubmed: 28880238
J Cancer. 2015 Sep 03;6(11):1079-86
pubmed: 26516354
Int J Mol Sci. 2014 Sep 05;15(9):15767-77
pubmed: 25198900